Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00533117 |
Recruitment Status :
Completed
First Posted : September 21, 2007
Results First Posted : August 28, 2017
Last Update Posted : January 5, 2024
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Borderline Personality Disorder | Drug: Fluoxetine Behavioral: Dialectical Behavior Therapy Behavioral: Supportive psychotherapy | Phase 4 |
Borderline personality disorder (BPD) can be a serious and very complex condition. BPD affects 2% to 3% of the population and is more commonly diagnosed in young women. BPD is characterized by mood swings, impulsive behavior, difficulty controlling emotions, and acting out inappropriately either through self-harm or attempts of suicide. Other illnesses such as depression and anxiety are also very common in people diagnosed with BPD. Various treatments exist that aim to reduce self-harm and suicide among people with BPD. Dialectical behavior therapy (DBT), an outpatient behavioral therapy shown to help self-injurious patients with BPD, has become a popular treatment. Another useful treatment, the antidepressant fluoxetine, can help to regulate mood and diminish suicidal or self-destructive urges. Although combination treatments of DBT and fluoxetine are common, little research has been conducted on the effectiveness of this kind of combined treatment. The purpose of this study is to determine whether DBT and fluoxetine are more effective combined or alone in treating people with BPD.
All participants in this double-blind study will receive a psychiatric and medication evaluation prior to starting treatment. Participants taking psychiatric medications prior to the study will be slowly withdrawn from the medications over a period of 2 to 6 weeks. Psychological interviews and self-report questionnaires will be administered, taking approximately 5 to 10 hours to complete. Once all preliminary interviews and evaluations have been completed, each participant will be randomly assigned to one of the four following treatment groups:
- Group 1 will receive DBT and fluoxetine (Prozac). DBT teaches patients new skills to replace old coping strategies such as suicide attempts and self-injury. Participants will work with an individual therapist for 1 hour a week to learn these new skills. This group will also be expected to keep a weekly diary that will discuss their current mood; suicidal and self-harming urges; and possible use of medications, drugs, and alcohol. Once a week participants will engage in a 90-minute skills training group to review the skills learned during therapy. Homework will be assigned between sessions to review these new strategies and skills. Participants will meet regularly with a psychiatrist to receive fluoxetine, discuss any side effects, and adjust dosage if necessary.
- Group 2 participants will receive DBT and placebo medication.
- Group 3 participants will receive supportive therapy and fluoxetine. Supportive therapy is nondirective and focuses on strengths, coping abilities, and current areas of difficulty in life in an unstructured format. Participants in this group will meet with an individual therapist each week for 50 minutes. Patients will also be assigned to a psychiatrist to receive fluoxetine every other week.
- Group 4 participants will receive supportive psychotherapy and placebo medication.
All patients participating in this study will continue treatment for 12 months and will be evaluated bimonthly. After 12 months, participants will undergo neuropsychological testing to identify any changes that occurred over the last year. The clinical status of each participant will also be assessed at 18 and 24 months.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 91 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder |
Study Start Date : | March 2001 |
Actual Primary Completion Date : | January 2008 |
Actual Study Completion Date : | December 2012 |
Arm | Intervention/treatment |
---|---|
Experimental: Dialectical Behavior Therapy Fluoxetine
Dialectal behavior therapy (DBT) is a form of Cognitive behavior therapy (CBT) targeting suicidal and non-suicidal self injury in borderline personality disorder and is delivered over a 12 month period,and fluoxetine, a selective serotonin reuptake inhibitor (SSRI) that is given in standard dosing 20, 40, 60, 80 mg for 12 months.
|
Drug: Fluoxetine
Fluoxetine is administered in standard dosing 20, 40, 60, 80 mg increased monthly if tolerated
Other Name: Prozac Behavioral: Dialectical Behavior Therapy Dialectical Behavior Therapy is a form of CBT originally developed to treat suicidal and self injuring individuals with borderline personality disorder. Treatment consists of 2 sessions/week: individual psychotherapy and skills training group.
Other Name: DBT |
Placebo Comparator: Dialectical Behavior Therapy placebo
Dialectal behavior therapy and placebo Dialectal behavior therapy (DBT) is a form of Cognitive behavior therapy targeting suicidal and non-suicidal self injury in borderline personality disorder and is delivered over a 12 month period, and placebo for fluoxetine, an SSRI that is given in standard dosing 20, 40, 60, 80 mg for 12 months.
|
Behavioral: Dialectical Behavior Therapy
Dialectical Behavior Therapy is a form of CBT originally developed to treat suicidal and self injuring individuals with borderline personality disorder. Treatment consists of 2 sessions/week: individual psychotherapy and skills training group.
Other Name: DBT |
Experimental: Supportive therapy Fluoxetine
Supportive psychotherapy and fluoxetine Supportive therapy is a manualized psychotherapy aimed at strengthening coping skills and is delivered over a 12 month period, and fluoxetine, an SSRI that is given in standard dosing 20, 40, 60, 80 mg for 12 months.
|
Drug: Fluoxetine
Fluoxetine is administered in standard dosing 20, 40, 60, 80 mg increased monthly if tolerated
Other Name: Prozac Behavioral: Supportive psychotherapy Supportive therapy is a manualized form of psychotherapy designed to enhance individual's strengths and coping mechanisms while reducing distress. |
Active Comparator: Supportive therapy placebo
Supportive psychotherapy and placebo See above for descriptions.
|
Behavioral: Supportive psychotherapy
Supportive therapy is a manualized form of psychotherapy designed to enhance individual's strengths and coping mechanisms while reducing distress. |
- Suicide Attempts [ Time Frame: Assessed bimonthly ]Suicide attempt count total over the course of the 12 month treatment period (sum of 6 bimonthly assessments during the treatment phase)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Meets criteria for diagnosis of borderline personality disorder
- History of at least one suicide attempt or self-mutilation episode 12 months prior to study entry
- Experiences continued urges to self-mutilate or attempt suicide
- Stable living situation
- Use of effective birth control if sexually active
- Clinically stable enough to tolerate placebo condition
- Not participating in other forms of treatment during the study
Exclusion Criteria:
- Any current organic mental syndromes, lifetime schizophrenic or bipolar disorders, psychotic disorders, or mental retardation
- Inability to complete psychiatric interview due to lack of cooperation or lack of comprehension
- Unable to tolerate fluoxetine or DBT
- Currently receiving treatment for an acute medical illness or other debilitating problem, including substance abuse or anorexia nervosa
- History of major depression lasting more than 3 months
- Current Hamilton depression score above 22 and not receiving treatment
- Pregnant or breastfeeding
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00533117
United States, New York | |
New York State Psychiatric Institute | |
New York, New York, United States, 10032 |
Principal Investigator: | Barbara Stanley, PhD | Research Foundation for Mental Hygiene/Columbia University |
Responsible Party: | Beth Brodsky, Associate Director, New York State Psychiatric Institute |
ClinicalTrials.gov Identifier: | NCT00533117 |
Other Study ID Numbers: |
#5401R R01MH061017-02 ( U.S. NIH Grant/Contract ) |
First Posted: | September 21, 2007 Key Record Dates |
Results First Posted: | August 28, 2017 |
Last Update Posted: | January 5, 2024 |
Last Verified: | January 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
suicide self-mutilation fluoxetine |
placebo dialectical behavior therapy supportive therapy |
Self Mutilation Personality Disorders Borderline Personality Disorder Mental Disorders Wounds and Injuries Self-Injurious Behavior Behavioral Symptoms Fluoxetine Selective Serotonin Reuptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators |
Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Serotonin Agents Physiological Effects of Drugs Antidepressive Agents, Second-Generation Antidepressive Agents Psychotropic Drugs Cytochrome P-450 CYP2D6 Inhibitors Cytochrome P-450 Enzyme Inhibitors Enzyme Inhibitors |